Background and Purpose-Hepatocyte growth factor (HGF) is a potent angiogenic factor and may play a role in the development and progression of atherosclerotic lesions, the underlying mechanism of cardiovascular disease. However, there have been no prospective studies examining the relationship between HGF levels and risk of stroke. Methods-We conducted a nested case-control study (972 incident stroke cases and 1:1 age-matched and race-matched controls) to prospectively evaluate the association between plasma HGF and risk of ischemic stroke within the Women's Health Initiative Observational Study, a cohort of postmenopausal women aged 50 to 79 years. Results-Baseline HGF levels were correlated positively with body mass index, systolic blood pressure, low-density lipoprotein cholesterol, insulin resistance, and inflammatory markers, such as C-reactive protein, and inversely with high-density lipoprotein cholesterol (all PϽ0.05). Baseline HGF levels were higher among cases than controls (geometric means, 601.8 vs 523.2 pg/mL; Pϭ0.003). Furthermore, the risk of incident ischemic stroke was significantly greater among women in the highest vs lowest quartile of plasma HGF levels (OR, 1.46; 95% CI, 1.12-1.91; P trend ϭ0.003) in a conditional logistic regression model that adjusted for body mass index. These results were only slightly attenuated after further adjustment for additional stroke risk factors (OR, 1.39; 95% CI, 1.04 -1.85; P trend ϭ0.023). Conclusions-Circulating levels of HGF are associated with an increased risk of incident ischemic stroke, independent of obesity and other risk factors for cardiovascular disease, among postmenopausal women aged 50 to 79 years. (Stroke. 2010;41:857-862.)
H epatocyte growth factor (HGF), initially described as a mitogen for hepatocytes, 1,2 is a potent angiogenic factor and endothelium-specific growth factor that affects a wide range of tissues. Its receptor, a transmembrane tyrosine kinase encoded by the proto-oncogene, c-Met, is expressed by a variety of cell types (eg, epithelial cells, hepatocytes, and vascular endothelial cells). 3, 4 Activation of this receptor in vascular endothelial cells leads to cell dissociation and migration, proliferation, protease production, invasion, and neovascularization. 4 Through these functions, it is hypothesized that HGF may play a role in the natural history of atherosclerosis and hence the pathogenesis of cardiovascular disease (CVD), including ischemic stroke. 4 -7 Consistent with this view, recent data in humans have demonstrated expression of c-Met and HGF in atherosclerotic plaques. 8 Interestingly, serum levels of HGF correlate positively with several CVD risk factors, including obesity, 9 hypertension, 10 and insulin resistance, 11 and inversely with high-density lipoprotein (HDL) cholesterol. 11 Furthermore, cross-sectional data have suggested that serum HGF levels are higher in patients with acute ischemic stroke than in healthy controls. [12] [13] To the best of our knowledge, however, there have been no prospective studies that have evaluated this association. Thus, it is unclear whether high HGF levels are a risk factor for ischemic stroke or a result of it, and whether HGF is an independent risk factor for stroke or merely a marker for other CVD risk factors. To address these issues, we conducted a nested case-control study within the Women's Health Initiative Observational Study and evaluated the association between circulating HGF levels and risk ischemic stroke.
Subjects and Methods

Study Population
The Women's Health Initiative Observational Study is an ongoing ethnically and geographically diverse prospective study that includes long-term follow-up of 93 676 participants at 40 clinical centers in the United States to examine the risk factors for subsequent development of several health outcomes. 14 -16 Briefly, postmenopausal women aged 50 to 79 years were enrolled between 1993 to 1998. At baseline, women were queried about lifestyle factors, medical history, and personal habits. A physical examination was performed to obtain height, weight, and blood pressure. Fasting blood samples were collected, centrifuged, frozen on site at Ϫ70°C, and later shipped to a central specimen repository. As of September 2005, 4.7% of the original 93 676 Women's Health Initiative Observational Study subjects had been lost to follow-up.
The Hormones and Biomarkers Predicting Stroke Study
The Hormones and Biomarkers Predicting Stroke study was a nested case-control study based on the Women's Health Initiative Observational Study. The goal was to determine if baseline circulating levels of various biomarkers, including adipokines, novel lipoproteins, inflammatory cytokines, and hemostasis markers, were associated with risk of ischemic stroke. 17, 18 Women were ineligible if they had a history of myocardial infarction or stroke at baseline.
Medical records were obtained for all potential stroke events that were identified through self-report at annual contacts; adjudication was performed locally by trained physicians who assigned a diagnosis according to standardized criteria. Only stroke events that required hospitalization were considered as potential outcomes and transient ischemic attacks were not included. All locally adjudicated stroke events were sent for central adjudication by a team of study neurologists. Strokes were classified as ischemic or hemorrhagic on review of reports of brain imaging studies. Ischemic stroke was defined as the rapid onset of a persistent neurological deficit attributed to an obstruction lasting Ͼ24 hours without evidence of other causes, unless death supervened or unless there was a demonstrable lesion compatible with acute stroke on CT or MRI scan. The subtypes of ischemic stroke were classified using Trial of Org 10172 in Acute Stroke Treatment criteria 19 as large artery atherothrombosis, cardioembolic, lacunar (small vessel), or undetermined etiology.
A total of 972 incident ischemic stroke cases were identified from study baseline to July 1, 2003. One control was selected from the risk set at the time of the case diagnosis and matched to each case on age at baseline (Ϯ2 years), race/ethnicity, date of study enrollment (Ϯ3 months), and follow-up time.
Plasma HGF levels were measured by a multiplex assay (human adipokine panel B; Millipore). 20 The interassay coefficient of variation for HGF assay was 11.7%. We previously reported the 3-year intraindividual correlation coefficient of HGF in a separate study population to be 0.91 (95% CI, 0.86 -0.97), 21 indicating that circulating levels of HGF are relatively stable and that a single measurement at baseline may reflect an individual's long-term exposure to this growth factor.
Statistical Analysis
We first assessed the associations of HGF levels with reported risk factors for ischemic stroke (eg, obesity, smoking, and hypertension) among controls. These baseline characteristics were compared by quartiles of HGF using ANOVA and 2 test. Cases and controls were then compared with respect to the reported risk factors for ischemic stroke at baseline; because of the matched case-control design, univariable conditional logistic regression and paired t test were used.
Multivariable conditional logistic regression was used to evaluate if HGF levels were associated with risk of incident ischemic stroke while adjusting for confounding variables identified from the 2 analyses described. HGF was modeled in quartiles to avoid assuming linearity. Tests of linear trend across quartiles were conducted by assigning the median value for each category, fitting this as a continuous variable in the model, and assessing statistical significance using Wald test. The multivariable model adjusted for the following baseline covariates that were associated with ischemic stroke in this study population: body mass index (BMI; continuous), physical activity (metabolic equivalent tasks per week in quartiles), smoking, use of nonsteroidal antiinflammatory drugs, use of hypertension medication, systolic blood pressure (continuous), diabetes (self-reported treatment or a fasting glucose level Ն126 mg/dL), and history of coronary or artery disease (none, 1, or Ն2 of the following conditions: angina, congestive heart failure, coronary revascularization procedure, atrial fibrillation, or peripheral artery disease). Among all the biomarkers examined in Hormones and Biomarkers Predicting Stroke study, C-reactive protein (CRP) was the most robustly associated with the risk of ischemic stroke 17 ; therefore, we also evaluated the impact of additional adjustment for CRP on the HGF association with stroke. Certain risk factors were associated with ischemic stroke in previous studies (eg, triglycerides, lowdensity lipoprotein cholesterol level, and postmenopausal hormone therapy) or in our univariable analyses (eg, IL-6 and tumor necrosis factor-␣); however, they were no longer significant after adjusting for the aforementioned covariates and they were not included in the regression model. Finally, to evaluate if the association of HGF and ischemic stroke could be modified by other stroke risk factors (eg, BMI, hypertension, and CRP), interaction terms were included 1 at a time into the final multivariable model and their significance was determined by Wald test.
All statistical analyses were performed using SAS software version 9.1 (SAS Institute). PϽ0.05 was considered statistically significant.
Results
Circulating HGF levels were positively associated with CVD risk factors, such as age, BMI, waist circumference, diabetes, systolic blood pressure, total and low-density lipoprotein cholesterol, and homeostatic assessment for insulin resistance, and inversely associated with HDL cholesterol levels ( Table 1 ). In addition, relatively higher HGF levels were associated with increased levels of inflammatory markers, including CRP, IL-6, and tumor necrosis factor-␣. Table 2 shows the univariable comparisons between cases and controls. As expected, ischemic stroke was associated positively with many established CVD risk factors, namely current smoking, BMI, waist circumference, diabetes, history of coronary and arterial disease, systolic blood pressure, and homeostatic assessment for insulin resistance, and inversely with physical activity and HDL cholesterol levels. Furthermore, cases had higher levels of inflammatory markers than controls. Geometric mean levels of HGF were 601.8 pg/mL in cases and 523.2 pg/mL in controls (Pϭ0.003). Table 3 shows the association between quartiles of HGF levels and risk of incident stroke. In the conditional logistic regression model accounting for only the matching factors (age and race/ethnicity), the OR for incident stroke with increasing quartiles of HGF were 1.0, 1.13, 1.38, and 1.49 (P for trendϭ0.001). Because HGF is an adipokine secreted by adipocytes, we added BMI into the model to examine whether HGF was merely a marker for adiposity or if its effect on risk of stroke was independent of adiposity. The HGF-stroke association was only slightly attenuated when BMI was adjusted for in the model, with the OR comparing the fourth to the first quartile of HGF being 1.46 (95% CI, 1.12-1.91; P for trendϭ0.003). This association remained significant even after additional adjustment for established risk factors for stroke. The OR between extreme quartiles of HGF was 1.39 (95% CI, 1.04 -1.85; P for trendϭ0.023). Further adjustment for CRP did not impact the HGF results. The OR for ischemic stroke comparing the fourth to the first quartile was 1.37 (95% CI, 1.02-1.83; P for trendϭ0.026). In addition, we did not observe any effect modification of the HGF-stroke association by the established stroke risk factors, and the results did not vary by subtype of ischemic stroke (data not shown).
Discussion
In this prospective study, we found circulating HGF levels to be positively associated with risk of ischemic stroke among postmenopausal women after accounting for established risk factors. HGF may increase the risk of ischemic stroke by promoting progression of atherosclerotic lesions, a critical step in the development of CVD, through its function as a potent angiogenic factor and its role in stimulating migration of vascular endothelial cells. High HGF levels, either in systemic circulation or locally induced by low-density lipoprotein cholesterol within atherosclerotic plaques, may lead to plaque neovascularization. 8, 22 Neovascularization, in turn, facilitates infiltration of leukocytes and inflammatory stimuli, which further enhance angiogenesis in atherosclerotic lesions. 23, 24 The resulting increase in microvascular density and chronic inflammation may contribute to plaque instability, such as intraplaque hemorrhage and plaque rupture, 23 which then lead to an acute ischemic stroke.
Previous studies provided initial data linking HGF with atherosclerosis and ischemic stroke. HGF protein was detected within carotid atherosclerotic lesions but not in normal vessels, 25 and circulating HGF levels were correlated with severity of carotid atherosclerosis measured by intima-medial thickness. 7 Further, a single nucleotide polymorphism in the intronic region of the HGF gene (T43839A) was associated with carotid atherosclerosis in women. 26 Two other studies found that circulating HGF was elevated among cases with acute ischemic stroke compared to controls. 12, 13 However, all these previous data were from cross-sectional studies with small sample sizes (Ͻ30 patients). Our nested case-control study provided prospective data supporting the role of HGF in pathogenesis of ischemic stroke. Our study and most previous studies found that HGF was associated with several CVD risk factors. As an adipokine expressed by white adipose tissue, [27] [28] [29] HGF levels are positively correlated with BMI in several studies. 9,11,30 -32 In addition, HGF levels have been observed to correlate positively with levels of insulin, insulin resistance, 11, 31 blood pressure, and triglyceride; however, they are inversely correlated with HDL cholesterol. 11, 31, 32 High levels of HGF have also been associated with increased severity of hypertension, 33-35 type 2 diabetes, 32 and increasing numbers of abnormalities in the components of the metabolic syndrome. 11, 32 In our study, the association between HGF and ischemic stroke remained significant after adjusting for other CVD risk factors in a multivariable regression model; after accounting for the effect of HGF, the associations of these CVD risk factors with stroke were unchanged. Therefore, it seems unlikely that circulating levels of HGF are simply a marker for known CVD risk factors. Moreover, many of these adjusted CVD risk factors are related to obesity (eg, diabetes, CRP, systolic blood pressure, and history of coronary artery diseases), so our multivariable results also support the notions that even though HGF is an adipokine, the mechanism underlying its association with ischemic stroke may go beyond the obesity-metabolic pathway and involve the potent angiogenic bioactivity of HGF.
Nevertheless, the strength of association between HGF and stroke (adjusted OR, 1.39) was moderate in comparison with other established risk factors. For example, in our multivariable regression model, the adjusted OR were 1.72 for diabetes and 2.33 for smoking (data not shown). It is possible that HGF may have limited value above and beyond those from the established risk factors in identifying individuals at risk for stroke.
Our study has a few limitations that warrant discussion. First, HGF might be a marker of other risk factors yet to be identified rather than a causal factor in the pathogenesis of ischemic stroke. Second, the relationship of circulating levels of HGF with those within the target tissue is not clear and will require further investigation. Last, this study was conducted among postmenopausal women, and our results need to be confirmed in other populations, particularly premenopausal women and men.
In conclusion, our study demonstrated a prospective association between relatively high plasma HGF levels and subsequent development of ischemic stroke among postmenopausal women aged 50 to 79 years, independent of established stroke risk factors. Future studies, including studies in men and in premenopausal women, are needed to further elucidate the role of HGF in the etiopathogenesis of ischemic stroke. 
